Hard to justify the 50 x MC of MSB compared to CYP. If the GvHD phase 2 trial continues to demonstrate outstanding efficacy and safety, it's safe to assume it will quickly replace ruxolitinib as SoC. Ruxo has many applications, with GvHD accounting for 17% of total income. That's circa $500M USD per annum. Frankly, the potential pipeline of indications appears immense.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
17.0¢ |
Change
-0.010(5.56%) |
Mkt cap ! $38.41M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 17.0¢ | 16.5¢ | $21.40K | 127.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 425750 | 16.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 90178 | 3 |
View Market Depth
| Last trade - 14.06pm 13/06/2025 (20 minute delay) ? |
| CYP (ASX) Chart |